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ABSTRACT
Background. It is unknown whether the addition of antiandrogen therapy (AAT) to late salvage radiation therapy
(sRT) can lead to oncological outcomes equivalent to that
of early sRT in men with recurrent prostate cancer (CaP)
after surgery.
Methods. Data on 670 men who participated in the
Radiation Therapy Oncology Group (RTOG)-9601 trial
and who experienced biochemical recurrence were
extracted using the National Clinical Trials Network
(NCTN) data archive platform. Patients were stratified into
four treatment groups: early sRT (pre-sRT prostate-specific
antigen [PSA] \ 0.7 ng/mL) and late sRT (pre-sRT PSA
C 0.7 ng/mL) with/without concomitant AAT, based on
cut-offs reported in the original trial. Time-varying Cox
proportional hazards and Fine–Gray competing-risk
regression analyses assessed the adjusted hazards of overall
mortality, CaP-specific mortality, and metastasis among
the four treatment groups.
Results. At 15-years (median follow-up of 14.7 years), for
patients treated with early sRT, early sRT with AAT, late
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sRT, and late sRT with AAT, the overall mortality, CaPspecific mortality, and metastasis rates were 22.9, 22.8,
40.1, and 22.9% (log-rank p = 0.0039), 12.1, 3.9, 22.7, and
8.0% (Gray’s p = 0.0004), and 18.8, 14.6, 35.9, and 19.5%
(Gray’s p = 0.0004), respectively. Time-varying multivariable adjusted analysis demonstrated increased hazards
of overall mortality in patients receiving delayed sRT
versus early sRT (hazards ratio [HR] 1.49, 95% confidence
interval [CI] 1.02–2.17); however, no difference remained
after the addition of concomitant AAT to late sRT (HR
0.85, 95% CI 0.55–1.32, referent early sRT). Likewise, the
hazards of cancer-specific mortality and metastatic progression were worse for late sRT when compared with
early sRT, but were no different after the addition of AAT
to late sRT.
Conclusions. Poorer outcomes associated with late sRT in
men with recurrent CaP may be rescued by delivery of
concomitant AAT.

Men who experience biochemical failure after radical
prostatectomy for localized prostate cancer (CaP) are recommended salvage radiation therapy (sRT) according to
the American and European urologic and radiation oncology societal guidelines.1–3
With regard to sRT, early initiation, usually defined as
sRT at or below the post-prostatectomy prostate-specific
antigen (PSA) value of 0.5 ng/mL, is advised. This is based
on data from multiple retrospective studies demonstrating

A. Sood et al.

superior outcomes in patients who are administered early
sRT as opposed to those who are not treated or administered late sRT.4–6 Based on recent level 1 evidence,7 it is
also recommended that these men be offered concomitant
anti-androgen therapy (AAT), as certain subgroups may
derive benefit from it. Hence, in an ideal scenario, a patient
who experiences biochemical recurrence following radical
prostatectomy should receive early sRT (PSA B 0.5 ng/
mL) at the least, with/without concomitant AAT.
However, this is not always the case in the real-world.
The variable natural history of CaP progression following
biochemical failure,8 as well as pragmatic issues such as
patients’ preferences, physicians’ beliefs, socioeconomic
barriers to timely care, loss to follow-up, etc., often limit
timely institution of salvage therapy. A substantial proportion of patients (close to 50%)4,5 hence end up
presenting or agreeing to salvage treatment later in their
disease course, when their PSA values are well beyond
0.5 ng/mL. In these patients, there is a concern that the
therapeutic window for salvage treatment may have been
lost, and therapy with ‘delayed’ sRT, even with the addition of AAT, may not be able to overcome the time delay in
initiation of sRT.
We designed the current study to investigate whether
this concern is true or not. Specifically, we sought to
answer the question ‘Could patients suffering biochemical
recurrence and receiving late sRT be rescued with synchronous use of AAT to achieve outcomes at par with the
patients who received early sRT?’. We leveraged data from
the Radiation Therapy Oncology Group (RTOG)-9601
clinical trial to answer our question. We hypothesized that
the answer to our question would be yes, and hoped that
our study would provide information to help patients
considering delayed sRT with or without concomitant AAT
make an informed, shared treatment decision.
METHODS
Data Source, Treatment Protocols, and Follow-Up
The data were obtained from the National Cancer
Institute’s (NCI’s) National Clinical Trials Network
(NCTN) data archive platform and Project Data Sphere
(PDS). These data repositories were specifically created
and made freely available to the public to promote collaborative analyses of trial data and hasten the discovery of
new and more effective anticancer treatments.9
A detailed description of the RTOG-9601 trial cohort
(n = 760) has been previously published.7 Briefly, the trial
recruited patients at high risk for biochemical failure, i.e.
patients with locally advanced CaP or organ-confined disease with positive surgical margin at radical prostatectomy,

who ultimately developed biochemical failure postprostatectomy. All patients were node-negative. Biochemical failure was defined as a PSA value between 0.2 and
4.0 ng/mL postoperatively. All patients had a Karnofsky
performance score C 80, no previous chemotherapy or
radiation therapy for CaP, and no previous hormone therapy other than short-term preoperative hormonal therapy.
Patients had a negative bone scan and computed tomography (CT) scan at the time of enrollment. At
randomization, these patients with biochemical failure
were either assigned to sRT and bicalutamide 150 mg daily
for 2 years or sRT and placebo. sRT was started within 12
weeks of randomization with a total dose of 64.8 Gy to the
prostatic fossa. Patients were assessed with history, physical examination, biochemical tests, and imaging before
and after sRT. Subsequent follow-up evaluation occurred
every 3 months for 2 years, then every 6 months for 3 years
and yearly afterwards.
Study Population and Treatment Groups
Of the 760 patients who were part of the RTOG-9601
trial, 670 (88.2%) experienced PSA recurrence, while the
remaining 90 (11.8%) experienced persistence. The latter
were excluded from the current study as we wanted to
focus solely on patients who experienced biochemical
recurrence (in comparison with a similar study by Dess
et al. that included all biochemical failure patients, i.e.
patients with biochemical recurrence and persistence10).
These 670 patients (Fig. 1) were divided into four groups:
early sRT alone (post-prostatectomy PSA at sRT \ 0.7 ng/
mL; n = 190), early sRT with concomitant AAT (n = 204),
late sRT alone (post-prostatectomy PSA at sRT C0.7 ng/
mL; n = 142), and late sRT with concomitant AAT
(n = 134). It should be noted that AAT was started concomitantly with sRT in those who were randomized to the
bicalutamide arm; hence, patients in the early sRT/AAT
arm received sRT ? bicalutamide at a PSA value of \ 0.7,
while patients in the late sRT/AAT arm received sRT ?
bicalutamide at a PSA value of C 0.7.
Covariates
In this study, covariates were categorized as reported in
the original trial7 and consisted of age at randomization,
race, Karnofsky performance score, pathologic Gleason
score, pathological T (pT) stage, surgical margin status,
time to biochemical recurrence from surgery, time to salvage treatment from biochemical recurrence, pre-sRT PSA
(\ 0.7 ng/mL [early] vs. 0.7–4.0 ng/mL [late]), and receipt
of bicalutamide versus placebo.
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FIG. 1 Final study population
and treatment groups. sRT
salvage radiation therapy, PSA
prostate-specific antigen

760 patients that were part of the original
RTOG 9601 trial
90 patients excluded as these patients
had persistance of prostate-specific
antigen after radical therapy
Patients eligible for the study;
n=670 (those with biochemical recurrence)

4 treatment groups

Late sRT (sRT at
PSA >=0.7 ng/mL)

Early sRT (sRT at
PSA <0.7 ng/mL)
Placebo
N=190

Bicalutamide
N=204

Outcome Measures
The endpoints of interest, as specified in the trial protocol, were (1) overall mortality, defined as death from any
cause; (2) CaP-specific death; (3) metastatic disease progression, defined as radiographic evidence of visceral or
bony disease; (4) local disease recurrence, defined as
development of a palpable mass in the prostatic fossa
determined by means of clinical examination; and (5)
functional adverse outcomes, including bowel complications (rectal urgency, diarrhea, and/or hematochezia),
bladder complications (urinary frequency, dysuria, hematuria, and/or incontinence), and new-onset impotence;
adverse reactions occurring within 90 days of the start of
sRT were scored using the RTOG Acute Radiation Morbidity Scoring Criteria and reactions beyond 90 days were
scored using the RTOG Late Radiation Morbidity Scoring
Criteria.
Statistical Analyses
Descriptive statistics were reported using frequencies
and proportions for categorical variables, and medians and
interquartile range (IQR) for continuous variables. Chisquare and Kruskal–Wallis tests were used to evaluate the
statistical significance of differences in categorical and
continuous variables, respectively.
Cumulative incidence and Kaplan–Meier methods were
used to generate 15-year estimates (start time was set at
radical prostatectomy) and assess differences in local disease recurrence, metastatic disease progression, CaPspecific mortality, and overall mortality rates among the
four study groups. Cumulative incidence analyses were
used for the former three endpoints, as mortality is a

Placebo
N=142

Bicalutamide
N=134

competing outcome for these endpoints (i.e. a mortality
event from another cause precludes local/metastatic failure
and death from CaP). However, for overall mortality,
standard Kaplan–Meier survival analysis was conducted as
the competing outcome relationship is unidirectional (i.e.
local/metastatic disease occurrence or CaP-specific death
does not preclude an overall mortality event).
For adjusted analyses, time-varying non-parsimonious
Fine–Gray competing-risk and Cox proportional hazards
regression modeling was performed to estimate the relative
hazards of local disease recurrence, metastatic disease
progression, CaP-specific mortality, and overall mortality
among the four treatments groups. Similar to the univariable analyses, Fine–Gray competing-risk analyses were
utilized for the former three endpoints, while Cox proportional hazards analysis was used for overall survival.
Non-parsimonious multivariable logistic regression modeling was performed to estimate the relative odds of early
and late functional adverse events among the four treatment groups. Each model (Cox proportional, Fine–Gray,
and multivariable logistic) controlled for age, race,
Karnofsky performance score, pathologic T stage, pathologic Gleason score, surgical margin status, and time to
biochemical recurrence, in addition to the primary independent variable of pre-sRT PSA level ? use of AAT (the
four treatment groups). It is noteworthy that our primary
independent variable was treated as a time-varying factor
to account for the immortal time bias that can introduced
by time-fixed analysis.11 Figure 2 provides further details
on the time-varying survival analyses.12
All statistical analyses were performed using SAS 9.3
(SAS Institute, Cary, NC, USA). A two-sided statistical
significance was defined as a p-value \ 0.05. An Institutional Review Board waiver was obtained before the study
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Treatment

Early sRT with or
without
concomitant AAT

Radical
prostatectomy

Early
biochemical
recurrence

Outcome

Late
biochemical
recurrence

Late sRT with or
without
concomitant AAT
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Study entry:
at the time fo
radical
prostatectomy

1

2

Follow-up time

The follow-up was started from the time of radical prostatectomy, and the “treatment” was considered a time-dependent predictor of the “outcome”, to avoid immortal time bias

FIG. 2 A multistate model of treatment strategies that was
constructed to account for the immortal time bias. This bubble
diagram demonstrates how patients were traced over time within the
multistate model according to treatment and survival history. Note:
Each bubble represents a possible health state. The included health
states were mutually exclusive, meaning that at any given time point a
patient could reside in only one health state. Arrows refer to a
transition in health states as time evolves, i.e. treatment initiation
(early or late sRT with/without AAT) or experiencing an adverse

outcome (local recurrence, metastasis, CaP death, or overall death).
All patients started in the alive-without-recurrence state of status postradical prostatectomy and subsequently moved to a post-treatment
state at the time sRT was initiated. Patients who experienced an
adverse outcome then moved to the ‘outcome’ state (path #1), an
absorbing health state, and patients who survived remained in their
post-treatment state until the end of the study or lost to follow-up
(right censored, path #2). sRT salvage radiation therapy, AAT antiandrogen therapy, CaP prostate cancer

was conducted, in accordance with institutional regulations
on dealing with previously collected de-identified data.

15-Year Overall Mortality, Prostate Cancer-Specific
Mortality, and Disease Progression Rates

RESULTS

The median follow-up was 14.7 years. In Kaplan–Meier
analysis, the 15-year overall mortality rates were 22.9,
22.8, 40.1, and 22.9% (log-rank p = 0.0039) (Fig. 3a) in
the early sRT, early sRT with AAT, late sRT, and late sRT
with AAT groups, respectively.
In cumulative incidence analyses, the 15-year CaPspecific mortality rates were 12.1, 3.9, 22.7, and 8.0%
(Gray’s p = 0.0004) (Fig. 3b) in the early sRT, early sRT
with AAT, late sRT, and late sRT with AAT groups,
respectively. Similarly, the 15-year metastatic and local
disease progression rates in the early sRT, early sRT with
AAT, late sRT, and late sRT with AAT groups were 18.8,
14.6, 35.9, and 19.5% (Gray’s p = 0.0004) (Fig. 3c), and
3.8, 1.2, 8.9, and 2.1% (Gray’s = 0.0431) (Fig. 3d),
respectively.

Baseline Characteristics
Table 1 provides details on the demographic and disease
characteristics of the patients in the four treatment groups.
The median time to biochemical recurrence was similar in
the four groups (p = 0.375), ranging between 1.3 and
1.6 years. The median time to treatment from biochemical
recurrence was predictably longer for patients in the late
sRT groups, i.e. 1–1.1 years, compared with 0.6 years for
the early sRT groups (p = 0.0001). Patients were otherwise
well-matched in all baseline and disease characteristics,
including pT stage (p = 0.107), pathological Gleason score
(p = 0.930), surgical margin status (p = 0.714), and
Karnofsky performance score (p = 0.589), except for age
(p = 0.014).
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TABLE 1 Baseline characteristics in patients with prostate cancer disease experiencing biochemical recurrence after radical prostatectomy,
stratified by early versus late salvage radiation therapy with/without concomitant anti-androgen treatment; RTOG-9601 trial data (n = 670)
Overall

Early sRT
PSA \ 0.7 ng/mL

Early sRT
PSA \ 0.7 ng/mL

Late sRT
PSA 0.7–4.0 ng/mL

Late sRT
PSA 0.7–4.0 ng/mL

p-value

No AAT [n = 190]

AAT [n = 204]

No AAT [n = 142]

AAT [n = 134]

1.4 (0.4–2.8)

1.4 (0.4–2.9)

1.6 (0.4–3.9)

1.3 (0.2–3.7)

0.3754

0.8 (0.7–1)

0.6 (0.5–0.9)

0.6 (0.5–0.7)

1.1 (0.9–1.1)

1 (0.9–1.4)

0.0001

Age, years
B 59

163 (24.33)

55 (28.95)

50 (24.51)

24 (16.9)

34 (25.37)

0.0141

60–69

339 (50.6)

98 (51.58)

107 (52.45)

66 (46.48)

68 (50.75)

168 (25.07)

37 (19.47)

47 (23.04)

52 (36.62)

32 (23.88)

White

596 (88.96)

165 (86.84)

191 (93.63)

127 (89.44)

113 (84.33)

African American

56 (8.36)

19 (10)

10 (4.9)

12 (8.45)

15 (11.19)

Other

18 (2.69)

6 (3.16)

3 (1.47)

3 (2.11)

6 (4.48)

Time, surgery to PSA elevation, years
Median (IQR)

1.4 (0.3–3.1)

Time, PSA elevation to treatment, years
Median (IQR)

C 70
Race

0.1854

Karnofsky performance score
B 90

161 (24.03)

46 (24.21)

43 (21.08)

39 (27.46)

33 (24.63)

100

509 (75.97)

144 (75.79)

161 (78.92)

103 (72.54)

101 (75.37)

0.5890

T2

228 (34.03)

59 (31.05)

80 (39.22)

52 (36.62)

37 (27.61)

T3

442 (65.97)

131 (68.95)

124 (60.78)

90 (63.38)

97 (72.39)

2–6
7

186 (27.76)
375 (55.97)

52 (27.37)
110 (57.89)

61 (29.9)
112 (54.9)

37 (26.06)
79 (55.63)

36 (26.87)
74 (55.22)

8–10

108 (16.12)

28 (14.74)

30 (14.71)

26 (18.31)

24 (17.91)

509 (75.97)

144 (75.79)

158 (77.45)

110 (77.46)

97 (72.39)

0.7140
NA

pT stage
0.1079

pGleason score
0.9302

Surgical margins
Positive

PSA level at treatment, ng/mL
\ 0.7

394 (58.81)

190 (100)

204 (100)

0 (0)

0 (0)

0.7–1.5

193 (28.81)

0 (0)

0 (0)

99 (69.72)

94 (70.15)

[ 1.5–4.0

83 (12.39)

0 (0)

0 (0)

43 (30.28)

40 (29.85)

Data are expressed as n (%) unless otherwise specified
sRT salvage radiation therapy, PSA prostate-specific antigen, AAT anti-androgen therapy, NA not available, IQR interquartile range

Rescue of Oncological and Survival Outcomes
by Concomitant Anti-Androgen Therapy in Patients
Receiving Late Salvage Radiation Therapy
Time-varying Cox regression analysis demonstrated that
the hazards of overall mortality were significantly worse in
patients receiving late sRT compared with those receiving
early sRT (hazards ratio [HR] 1.49, 95% confidence
interval [CI] 1.02–2.17); however, the hazards were no
different among patients who received late sRT with AAT
versus early sRT (HR 0.85, 95% CI 0.55–1.32) (Table 2,
Part A).
Time-varying Fine–Gray competing-risk analysis similarly demonstrated that the increased hazard of CaP-

specific mortality in patients undergoing late sRT could be
rescued by delivery of concomitant AAT. The HR of CaPspecific mortality in the late sRT-only patients compared
with early sRT was 1.64 (95% CI 1.08–2.85), while the HR
in the late sRT with concomitant AAT patients was 0.62
(95% CI 0.31–1.22; referent early sRT). Similarly, the HR
of metastasis in patients receiving late sRT compared with
early sRT was 1.93 (95% CI 1.23–3.03). However, the
hazards were no different in patients receiving late sRT
with concomitant AAT versus early sRT (HR 0.86, 95% CI
0.51–1.46). On the other hand, the hazards of local disease
recurrence did not differ among any of the four treatment
groups (Table 2, Part A). Table 2, Part B, serves as a
straightforward ‘visual aid’ to compare the outcomes
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Early sRT (PSA <0.7) + Placebo
Early sRT (PSA <0.7) + Bicalutamide
Late sRT (PSA 0.7 to 4.0) + Placebo
Late sRT (PSA 0.7 to 4.0) + Bicalutamide
15-year overall mortality rate (95% confidence intervals)

Overall mortality

0.8
0.6

Early sRT + Placebo

22.9% (16.2 - 29.1%)

Early sRT + Bicalutamide

22.8% (16.1 - 29.0%)

Late sRT + Placebo

40.1% (30.7 - 48.2%)

Late sRT + Bicalutamide

22.9% (14.5 - 30.1%)

Log-rank p=0.0039

0.4
0.2

(b) 1.0
Prostate cancer specific mortality

(a) 1.0

0.0

15-year Cap specific mortality rate (95% confidence intervals)

0.8

Early sRT + Placebo
Early sRT + Bicalutamide
Late sRT + Placebo
Late sRT + Bicalutamide

12.1% (8.1 - 18.3%)
3.9% (1.8 - 8.1%)
22.7% (16.7 - 30.9%)

Gray’s p=0.0004

8.0% (4.1 - 15.6%)

0.6
0.4
0.2
0.0

0

5

10
Time (yrs)

(c) 1.0

15

20

Early sRT (PSA <0.7) + Placebo
Early sRT (PSA <0.7) + Bicalutamide
Late sRT (PSA 0.7 to 4.0) + Placebo
Late sRT (PSA 0.7 to 4.0) + Bicalutamide

0

5

Early sRT + Placebo

0.6

18.8% (13.5 - 26.2%)

Early sRT + Bicalutamide

14.6% (9.8 - 21.9%)

Late sRT + Placebo

35.9% (27.3 - 47.2%)

Late sRT + Bicalutamide

19.5% (14.1 - 27.1%)

Log-rank p=0.0004

0.4
0.2
0.0

15

20

Early sRT (PSA <0.7) + Placebo
Early sRT (PSA <0.7) + Bicalutamide
Late sRT (PSA 0.7 to 4.0) + Placebo
Late sRT (PSA 0.7 to 4.0) + Bicalutamide
15-year local disease progression rate (95% confidence intervals)

15-year metastatic disease progression rate (95% confidence intervals)

0.8

10
Time (yrs)

(d) 1.0
Local disease progression

Metastic disease progression

Early sRT (PSA <0.7) + Placebo
Early sRT (PSA <0.7) + Bicalutamide
Late sRT (PSA 0.7 to 4.0) + Placebo
Late sRT (PSA 0.7 to 4.0) + Bicalutamide

0.8

Early sRT + Placebo

0.6

3.8% (1.4 - 10.5%)

Early sRT + Bicalutamide

1.2% (0.3 - 5.5%)

Late sRT + Placebo

8.9% (3.8 - 20.7%)

Late sRT + Bicalutamide

2.1% (0.5 - 8.5%)

Gray’s p=0.0431

0.4
0.2
0.0

0

5

10
Time (yrs)

15

20

0

5

10
Time (yrs)

15

20

FIG. 3 Kaplan–Meier analysis of overall mortality with 15-year
estimates (a), and cumulative incidence analyses of CaP-specific
survival (b), metastatic disease failure (c), and local disease failure
(d) with 15-year estimates; the four groups correspond to early sRT,

early sRT with concomitant AAT, late sRT, and late sRT with
concomitant AAT (RTOG-9601 trial data). CaP prostate cancer, sRT
salvage radiation therapy, AAT anti-androgen therapy, PSA prostatespecific antigen

between the early sRT plus concomitant AAT and late sRT
plus concomitant AAT groups, and demonstrates that the
rescue of oncological outcomes with AAT use in delayed
sRT is actually at par with the outcomes of patients
receiving early sRT with concomitant AAT. Table 2, Part
C, similarly simplifies the comparison between the late sRT
and late sRT with concomitant AAT groups, and demonstrates significant improvement in all oncological
outcomes, except local disease recurrence, when concomitant AAT is administered to patients receiving delayed
sRT.

bladder toxicities were also equivalent among the four
treatment groups (Table 3).

Functional Adverse Effects
In time-varying multivariable analyses, delayed sRT
with concomitant AAT was not associated with increased
odds of new-onset sexual dysfunction when compared with
early sRT alone (odds ratio [OR] 1.26, 95% CI 0.68–2.34).
Other adverse events including acute and late bowel and

DISCUSSION
The key finding of our study is the demonstration of the
ability of AAT to rescue oncological and survival outcomes in patients who receive delayed sRT after
experiencing biochemical recurrence post-prostatectomy.
The improvement is substantial and leads to survival rates
at par with that of men who received early sRT with or
without concomitant AAT. Patients undergoing late sRT
had a 48.6, 64.2, and 93.2% increase in hazard of overall
death, death from CaP, and metastatic spread, respectively,
compared with patients who received early sRT; however,
these differences were completely negated once concomitant AAT was delivered alongside late sRT.
Our study also shows that the addition of AAT to late
sRT does not increase the risk for new-onset impotence or
bowel or bladder dysfunction.
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TABLE 2 Time-varying Cox proportional hazards and Fine–Gray
competing-risk pairwise regression analyses evaluating the hazards of
mortality and disease progression among patients experiencing

biochemical recurrence after radical prostatectomy and undergoing
early versus late salvage radiation therapy with/without concomitant
anti-androgen treatment; RTOG-9601 trial data [n = 670]

Hazards ratio (95% confidence interval)
Early sRT
PSA \ 0.7 ng/mL

Early sRT
PSA \ 0.7 ng/mL

Late sRT
PSA 0.7–4.0 ng/mL

Late sRT
PSA 0.7–4.0 ng/mL

No AAT [n = 190]

AAT [n = 204]

No AAT [n = 142]

AAT [n = 134]

Overall mortality

Ref.

1.025 (0.696–1.509),
p = 0.90

1.486 (1.017–2.174),
p = 0.04

0.850 (0.549–1.316),
p = 0.47

CaP-specific
mortality

Ref.

0.458 (0.235–0.892),
p = 0.01

1.642 (1.080–2.849),
p = 0.04

0.619 (0.314–1.223),
p = 0.25

Metastatic
progression

Ref.

0.750 (0.462–1.220),
p = 0.24

1.932 (1.230–3.034),
p \ 0.01

0.858 (0.505–1.459),
p = 0.57

Local failure

Ref.

0.316 (0.064–1.557),
p = 0.21

2.105 (0.742–5.970),
p = 0.10

0.481 (0.096–2.400),
p = 0.36

Overall mortality

0.976 (0.663–1.437),
p = 0.90

Ref.

1.451 (1.005–2.095),
p = 0.04

0.830 (0.541–1.274),
p = 0.34

CaP-specific
mortality

2.183 (1.121–4.254),
p = 0.01

Ref.

3.585 (1.893–6.788),
p \ 0.01

1.352 (0.627–2.915),
p = 0.24

Metastatic
progression

1.333 (0.820–2.167),
p = 0.24

Ref.

2.574 (1.596–4.153),
p \ 0.01

1.144 (0.653–2.002),
p = 0.83

Local failure

3.161 (0.642–15.56),
p = 0.21

Ref.

6.655 (1.418–31.24),
p \ 0.01

1.519 (0.211–10.91),
p = 0.62

Overall mortality

0.673 (0.460–0.984),
p = 0.04

0.689 (0.477–0.995),
p = 0.04

Ref.

0.572 (0.378–0.867),
p = 0.02

CaP-specific
mortality

0.609 (0.351–0.961),
p = 0.04

0.279 (0.147–0.528),
p \ 0.01

Ref.

0.377 (0.193–0.738),
p \ 0.01

Metastatic
progression

0.518 (0.330–0.813),
p \ 0.01

0.388 (0.241–0.627),
p \ 0.01

Ref.

0.444 (0.263–0.751),
p \ 0.01

Local failure

0.475 (0.167–1.347),
p = 0.10

0.150 (0.032–0.705),
p \ 0.01

Ref.

0.228 (0.049–1.055),
p = 0.07

Modela (part A)b

Modela (Part B)b

Modela (Part C)b

sRT salvage radiation therapy, PSA prostate-specific antigen, AAT anti-androgen therapy, CaP prostate cancer
a

Each model was adjusted for age, race, Karnofsky performance score, pathologic T stage, pathologic Gleason score, surgical margin status, and
time to biochemical recurrence, in addition to the primary independent time-varying variable of pre-sRT PSA ? use of AAT, except the model
for local failure where univariable time-varying Fine–Gray competing-risk modeling was undertaken as the number of local failure events were
\20, hence adjustments for the aforementioned variables would not have been statistically sound

b

Parts A, B and C of the table represent the same regression models, with the only change being in the referent used, to allow for easy pairwise
comparisons

To the best of our knowledge, these data have not been
previously published and may aid in the counseling of men
who experience biochemical recurrence following radical
prostatectomy. Our results offer hope to men who, whether
willingly or not, may have missed the window for early
sRT. These patients can be told that their chances of dying
from their cancer are \ 10% at 15 years, and no worse
compared with an earlier treatment with sRT, if they now
accept combination treatment with sRT and AAT.

Although our findings may be used to allay anxiety in
men whose PSA values are beyond 0.5 ng/mL, conversely
they may also be used to convince patients to go ahead with
early sRT. For example, patients who are experiencing
biochemical recurrence with PSA B 0.5 ng/mL, and who
are doubtful about whether to wait-and-watch or to start
early sRT, can be given the two therapeutically equivalent
options—early sRT or delayed sRT with AAT. The ultimate decision can be left up to the patients but they may be
told that by starting sRT earlier, they may obviate the need
for additional hormonal treatment later, and although AAT
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TABLE 3 Multivariable logistic regression analyses evaluating the
odds of bowel, bladder, and sexual adverse events among patients
experiencing biochemical recurrence after radical prostatectomy and
Modela

undergoing early versus late salvage radiation therapy with/without
concomitant anti-androgen treatment; RTOG-9601 trial data
[n = 670]

Odds ratio (95% confidence interval)
Early sRT
PSA \ 0.7 ng/mL

Early sRT
PSA \ 0.7 ng/mL

Late sRT
PSA 0.7–4.0 ng/mL

Late sRT
PSA 0.7–4.0 ng/mL

No AAT [n = 190]

AAT [n = 204]

No AAT [n = 142]

AAT [n = 134]

Ref.

1.193 (0.678–2.100), p = 0.54

0.634 (0.309–1.300), p = 0.21

1.258 (0.676–2.340), p = 0.47

Acute

Ref.

1.015 (0.678–1.519), p = 0.94

0.903 (0.575–1.417), p = 0.66

1.288 (0.818–2.029), p = 0.27

Late

Ref.

1.038 (0.684–1.574), p = 0.86

0.795 (0.503–1.255), p = 0.32

0.714 (0.451–1.130), p = 0.16

Ref.

0.597 (0.393–0.908), p = 0.02

0.681 (0.487–1.086), p = 0.11

0.805 (0.500–1.296), p = 0.37

Ref.

1.105 (0.739–1.651), p = 0.63

0.733 (0.465–1.153), p = 0.18

0.945 (0.601–1.485), p = 0.81

New-onset impotence
Bladder toxicity

Bowel toxicity
Acute
Late

sRT salvage radiation therapy, PSA prostate-specific antigen, AAT anti-androgen therapy, Ref. reference
a

Each model was adjusted for age, race, Karnofsky performance score, pathologic T stage, pathologic Gleason score, surgical margin status, and
time to biochemical recurrence, in addition to the primary independent time-varying variable of pre-sRT PSA ? use of AAT

does not seem to increase the risk of new-onset impotence,
its adverse effect on libido and gynecomastia are well
known.13 These patients may also be told that early sRT
will not affect the recovery of their urinary control
adversely, as shown by a recent study evaluating the effect
of timing of sRT on urinary control.14
Data presented at the European Society for Medical
Oncology Congress 2019 from the RADICALS (Radiotherapy and Androgen Deprivation in Combination after
Local Surgery),15 RAVES (Radiotherapy—Adjuvant versus Early Salvage),16 and GETUG-AFU17 trials indicate
that the adjuvant radiation therapy and early sRT may yield
similar outcomes in men at high risk for biochemical
recurrence. The final results have verified the initial findings,17–19 and it is therefore safe to surmise that now more
men will be recommended sRT and may find themselves
debating early versus late sRT; thus, the findings of this
study become even more timely. Furthermore, once the
onslaught of the current coronavirus disease 2019
(COVID-19) pandemic is over, it is reasonable to assume
that an increasing number of men worldwide will present
with higher recurrent PSA values than in the past. These
patients may benefit from the knowledge that a combination treatment can offer them an equivalent chance at cure
as early sRT.
Our study is not devoid of limitations, within the bounds
of which our findings should be interpreted. First, this study
represents a post hoc analysis of level 1 evidence, and thus
suffers from confounding and selection bias. However, the
four treatment groups studied in the present report were
quite well-matched at baseline (Table 1), and to account
for known confounders and immortal bias, we performed

time-varying adjusted analyses, which confirmed the
results of our univariable analyses. Furthermore, AAT use
consistently demonstrated benefit across all studied outcomes, whether overall mortality or cancer-specific
outcomes; taken together, these facts support the reliability
and validity of our findings. Another limitation of our study
is that the RTOG-9601 trial dataset available through the
NCTN data archive provided only limited information
regarding pre-sRT PSA; only a single value of PSA was
provided, in a categorical fashion (\ 0.7 vs. 0.7–1.5
vs. [ 1.5–4.0 ng/mL). Because of this, we were not able to
classify our patients using a more standard or traditional
pre-sRT PSA cut-off, such as that of 0.5 ng/mL. However,
on comparing baseline characteristics, including age, pT
stage, pathologic Gleason score, and surgical margins, of
our patients in the early sRT cohort with those in the other
published cohorts, where a pre-sRT PSA cut-off of B0.5
ng/mL was used,4–6 we found no major differences. Furthermore, although our cut-off was not exactly at PSA
B0.5 ng/mL (it was off by 0.1 ng/mL), the study still
provides a proof of principle, and, similarly, although the
survival estimates that we note in this study may not
wholly translate when using a different pre-sRT PSA cutoff for salvage treatment, the outcome patterns should still
hold true. Lastly, the trial included patients undergoing
sRT and AATs between the years 1998 and 2003. Substantial changes in radiation therapy techniques and
androgen deprivation have come about since then, and thus
the results may not be completely generalizable to the
contemporary patients undergoing sRT with/without hormonal treatment today. However, as reasoned above for the
pre-sRT cut-off, here too, the basic principles of therapy
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remain the same and any further variation in technique of
sRT or AAT pharmacology should affect the treatment
groups equally, thus preserving the overall message of the
study.
On the other hand, our study has several other
methodological strengths. We corrected for lead time and
immortal time biases by utilizing time-varying regression
analyses, which none of the prior studies on this subject
have done,10 and can lead to substantial errors.11 Furthermore, the data were derived from a trial with rigorous
patient follow-up, the follow-up duration was substantial
(median 14.7 years), and the study focused only on nodenegative localized CaP patients (in contrast to prior studies
that frequently included patients with nodal disease or
persistent PSA after surgery).10,20,21 Lastly, the outcomes
assessed were powerful and clinically meaningful, including overall survival, CaP-specific survival, and clinical
metastasis.
CONCLUSION
Ours is the first study to demonstrate that poorer outcomes associated with late sRT in men with recurrent CaP
after radical prostatectomy may be successfully rescued by
use of concomitant AAT.
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